Janssen Receives Complete Response Letter From U.S. FDA for Sirukumab Biologics License Application

HORSHAM, PA, September 22, 2017 – Janssen Biotech, Inc. (Janssen) announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) seeking approval of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news